Sarkomycin
Sarkomycin is a glutathione-targeting cytotoxic agent and antibacterial agent. Sarkomycin forms an addition product with glutathione, thereby reducing intracellular glutathione levels. Sarkomycin can induce cytoplasmic vacuolation, mitochondrial damage, cytoplasmic deformation, metaphase arrest, chromosomal abnormalities, nuclear degeneration, and nuclear fragmentation; it also modulates amino acid metabolism. Sarkomycin also inhibits anaerobic fermentation in affected cells in mice and inhibits cell growth in tissue culture, leading to the disappearance of mitotic cells, cell degeneration, and cell detachment from the glass surface. Sarkomycin can be used in research related to Yoshida ascites tumor, Ehrlich ascites tumor, Ehrlich carcinoma, and Yoshida rat sarcoma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 489-21-4
- Fòrmula: C7H8O3
- Peso molecular:140.14
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Sarkomycin (3.5 mg; i.p.; single dose) induces rapid, progressive cytological damage and marked alterations in free amino acid levels, including de novo glutamine appearance, in Ehrlich ascites tumor cells and fluid in A/He mice[1].
Sarkomycin (3.5 mg; i.p.; single dose) induces identical rapid cytological and amino acid alterations in Ehrlich ascites tumor cells and fluid in C57BL mice as observed in A/He mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pacific Farms Wistar (WP) (175 gm, Yoshida ascites tumor transplanted intraperitoneally 5 days prior)[1]
-
Dosage:50 mg
-
Administration:i.p.; single dose
-
Result:Reduced mitotic figures such that no normal mitotic figures were present by 120 minutes.
Induced cytoplasmic blebbing, chromosomal clumping, and scattering in metaphase cells by 30 minutes.
Caused severe cytoplasmic distortion, mitotic arrest at metaphase, and nuclear abnormalities by 60 minutes.
Resulted in over 50% of cells showing pyknotic chromatin aggregates by 120 minutes.
Greatly elevated cellular glutamine levels and induced glutamine appearance in ascitic fluid by 30 minutes, with further increases by 300 minutes.
Triggered progressive mitochondrial degeneration and marked intraperitoneal cellular reaction by 300 minutes.
-
Animal Model:Pacific Farms Wistar (WP) (Yoshida ascites tumor transplanted intraperitoneally 5 days prior)[1]
-
Dosage:30 mg/100 gm
-
Administration:i.p.; single dose
-
Result:Preserved tumor cells' ability to take up labeled glutamine and convert it to glutamic acid.
Caused slight decreases in aspartic acid and glutathione levels in cells.
Induced appearance of a new unidentified ninhydrin-reactive substance in cells.
-
Animal Model:A/He (35 gm average weight, Ehrlich ascites tumor transplanted intraperitoneally 48 hours prior)[1]
-
Dosage:3.5 mg
-
Administration:i.p.; single dose
-
Result:Induced cytoplasmic blisters, clumped/sticky chromosomes in metaphase cells, and chromonema-like structures in resting nuclei by 5 minutes.
Caused severe cytoplasmic blebbing and peaked abnormal nuclear structures by 10 minutes.
Triggered abnormal nucleus coalescence and degeneration, and elevated taurine levels in ascitic fluid by 20 minutes.
Resulted in extensive cytoplasmic damage and karyorrhexis, and marked elevations in cellular glutamine, valine, leucine, tyrosine, and lysine levels, plus elevated ascitic fluid glutamine, aspartic acid, taurine, and valine levels with decreased alanine and glycine levels by 40 minutes.
Eliminated all damaged cells, leaving a small number of normal-appearing tumor cells between 60 and 120 minutes.
Induced de novo glutamine appearance in cells, decreased glutathione levels, increased valine and leucine levels, and a new unidentified ninhydrin-reactive substance by 5 minutes.
-
Animal Model:C57BL (Ehrlich ascites tumor transplanted intraperitoneally 3 days prior)[1]
-
Dosage:3.5 mg
-
Administration:i.p.; single dose
-
Result:Induced cytoplasmic damage and nuclear abnormalities.
Triggered appearance of glutamine in cells, decreased glutathione levels, increased valine and leucine levels, and presence of an unidentified ninhydrin-reactive substance.
- Research Protocol for Infectious Diseases
- Nuclear DNA counterstaining and nuclear morphology staining
- Protocol for Cell Counting and Cell Density Analysis
- Somatic Cell Culture
- CCK-8/WST-8 Cell Proliferation Assay
- Cell Counting-Based Growth Curve Assay
- MTT Cell Proliferation Assay
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
No. CAS 489-21-4
-
Peso molecular 140.14
-
Fòrmula C7H8O3
-
SMILES
OC([C@H]1C(C(CC1)=O)=C)=O
-
Structure Classification
-
Initial Source
Streptomyces erythrochromogenes
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sarkomycin Related Classifications
HY-N21831 Related Classifications
Powered by Bioz